Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | CDKN2A R80* |
| Therapy | Palbociclib |
| Indication/Tumor Type | stomach carcinoma |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| CDKN2A R80* | stomach carcinoma | sensitive | Palbociclib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, a gastric carcinoma cell line harboring CDKN2A R80* was sensitive to Ibrance (palbociclib) both in culture and in cell line xenograft models (PMID: 26380006, PMID: 20952405). | 26380006 20952405 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (26380006) | CDK4/6 inhibitor suppresses gastric cancer with CDKN2A mutation. | Full reference... |
| (20952405) | COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. | Full reference... |